C
C

Cigna


Balita

AbbVie's Humira gets a U.S. rival, but costs could stay high

FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high Updates to clarify lower price may not be widely used, rather than widely available, and why By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited.
A
C

U.S. STOCKS A O Smith, Pentair, health insurers

BUZZ-U.S. STOCKS ON THE MOVE-A O Smith, Pentair, health insurers Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street rose on Tuesday as wage growth data indicated that the Federal Reserve's aggressive approach to taming inflation was taking hold ahead of a decision by the central bank, while gains on the Dow were limited by weak earnings updates.
C
G
I
M
N
P
Q
T
J
U
U
S
A
P

AbbVie's Humira gets a U.S. rival, but costs could stay high

FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high Updates with new CVS policy By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20-year-old drug, with two tiers of pricing.
A
C

AbbVie's Humira gets a U.S. rival, but costs could stay high

FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20-year-old drug, with two tiers of pricing.
A
C

U.S. earnings week ahead

DIARY-U.S. earnings week ahead Jan 27 (Reuters) - Diary of U.S. (.SPX) corporate earnings for the week ahead. ** Please Note - All times given are in U.S. EDT unless otherwise stated ** U.S. EARNINGS Start Date Start Time RIC Company Name Event Name 30-Jan-2023 16:05 WHR Whirlpool Corp Q4 2022 Whirlpool Corp Earnings Release 30-Jan-2023 AMC PFG.O Principal Financial Group Inc Q4 2022 Principal Financial Group Inc Earnings Release 30-Jan-2023 AMC ARE Alexandria Real Estate Equities Inc Q4 2022 Al
A
A
A
C
C
C
D
F
G
G
H
M
M
N
P
P
Q
Q
R
S
A
W
C
E
M
N
T
U
A
A
B
E
I
M
S
T
W
W
Z
A
A
A
A
B
C
C
C
D
F
G
I
O
P
P
S
T

CVS names new pharmacy services, consumer product chiefs

UPDATE 2-CVS names new pharmacy services, consumer product chiefs Adds background on company and new appointments Jan 23 (Reuters) - CVS Health Corp CVS.N said on Monday that David Joyner would return to head the U.S. diversified healthcare company's pharmacy services and tapped former Cigna Corp CI.N executive Amy Bricker as its chief product officer for consumer business.
C

CVS names new pharmacy services, consumer products chiefs

CVS names new pharmacy services, consumer products chiefs Jan 23 (Reuters) - CVS Health Corp CVS.N named David Joyner to head its pharmacy services and appointed former Cigna Corp CI.N executive Amy Bricker as chief product officer for consumer businesses, the company said on Monday. Reporting by Raghav Mahobe and Sriparna Roy in Bengaluru
C

Evernorth Names Adam Kautzner President, Express Scripts

BRIEF-Evernorth Names Adam Kautzner President, Express Scripts Jan 18 (Reuters) - Cigna Corp CI.N : EVERNORTH NAMES ADAM KAUTZNER PRESIDENT, EXPRESS SCRIPTS Source text for Eikon: ID:nPn6jQ9Qda Further company coverage: CI.N
C

Wall St set to open lower as earnings of big banks disappoint

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.) * JPMorgan reports profit miss * June PPI surges more than expected * Futures down: Dow 1.55%, S&P 1.29%, Nasdaq 0.82% By Amruta Khandekar and Bansari Mayur Kamdar July 14 (Reuters) - U.S. stocks were set to open lower on Thursday as downbeat earnings from big U.S.
C
G
U
U

Futures fall as JPMorgan, Morgan Stanley kick off earnings on sour note

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window.) * Futures down: Dow 1.35%, S&P 1.27%, Nasdaq 0.88% By Amruta Khandekar and Bansari Mayur Kamdar July 14 (Reuters) - U.S. stock index futures fell on Thursday after JPMorgan Chase & Co and Morgan Stanley kicked off the earnings season with downbeat results, adding to worries of a potential recession.
C
G
U
U

How far behind the curve exactly?

A look at the day ahead in markets from Julien Ponthus. On Friday, St. Louis Fed President James Bullard argued that the U.S. Federal Reserve is "not as far behind the curve as you might have thought". With inflation running over 6%, the jury is out on whether last week's 50 basis point rate hike is catching up with the curve or falling woefully behind.
A
C
U

Sell everything (except the dollar)!

A look at the day ahead in markets from Dhara Ranasinghe. When the blue-chip Dow Jones index slides more than 1,000 points on one day, U.S. Treasury yields jump as much as 20 basis points and Britain's pound drops more than 2%, you'd be forgiven for thinking that investors have gone into a sell everything mode. But with the safe-haven dollar at 20-year highs, there was at least one asset benefiting from Thursday's market mayhem.
A
C
U



Kundisyon

Mga Patok na Assets

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Gumagamit kami ng cookies para mabigyan ka ng mahusay na karanasan sa aming website. Magbasa pa o palitan ang iyong cookie settings.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.